Immunovant (IMVT) Cash from Investing Activities (2019 - 2026)
Immunovant (IMVT) reported Cash from Investing Activities of -$8000.0 for Q1 2026, up 96.02% on a YoY basis from -$4081.2 in Q1 2025, and up 96.02% quarter-over-quarter from -$201000.0 in Q1 2025.
Immunovant (IMVT) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Immunovant has reported Cash from Investing Activities for 8 years, with the latest figure at -$8000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 96.02% year-over-year to -$8000.0; the trailing twelve-month figure through Mar 2026 stood at -$8000.0 (up 98.95% YoY), and the FY2026 full-year result was -$8000.0, up 98.95% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$8000.0, up from -$201000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$8000.0 in Q1 2026, with the low at -$201000.0 in Q1 2025.
- Historically, Cash from Investing Activities has averaged -$103000.0 across 5 years, with a median of -$108000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities slumped 476.92% — and 2026, when it soared 96.02%.
- Immunovant's Cash from Investing Activities stood at -$98000.0 in 2022, then plunged by 33.67% to -$131000.0 in 2023, then slumped by 37.4% to -$180000.0 in 2024, then fell by 11.67% to -$201000.0 in 2025, then soared by 96.02% to -$8000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$8000.0 (Q1 2026), -$201000.0 (Q1 2025), and -$180000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | -8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,000.00 |
| Mar 31, 2026 | -8,000.00 |
| Mar 31, 2025 | -201,000.00 |
| Mar 31, 2025 | -201,000.00 |
| Dec 31, 2024 | -180,000.00 |
| Dec 31, 2024 | -180,000.00 |
| Sep 30, 2024 | -196,000.00 |
| Sep 30, 2024 | -196,000.00 |
| Jun 30, 2024 | -182,000.00 |
| Jun 30, 2024 | -182,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Dec 31, 2023 | -131,000.00 |
| Dec 31, 2023 | -131,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Jun 30, 2023 | -45,000.00 |
| Jun 30, 2023 | -45,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Mar 31, 2023 | -26,000.00 |